NCT01230385 - Safety And Tolerability Of Multiple Dose Lersivirine For 21 Days In Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Healthy Volunteers

Interventions

DRUG

Lersivirine

Lersivirine 500 mg QD fasted (wet granulated tablet) for 21 days

DRUG

Lersivirine

Lersivirine 500 mg QD fed (wet granulated tablet) for 21 days

DRUG

Lersivirine

Lersivirine 750 mg QD fasted (wet granulated tablet) for 21 days

DRUG

Lersivirine

Lersivirine 750 mg QD fed (wet granulated tablet) for 21 days

DRUG

Lersivirine

Lersivirine 500 mg QD fasted (dry granulated tablet) for 21 days

Trial Locations (2)

Pfizer Investigational Site, New Haven

Pfizer Investigational Site, Brussels